Serum apolipoprotein E level is not increased in Alzheimer's disease: the Rotterdam study

被引：54
作者：
Slooter, AJC
de Knijff, P
Hofman, A
Cruts, M
Breteler, MMB
Van Broeckhoven, C
Havekes, LM
van Duijn, CM
机构：
[1] Erasmus Univ, Sch Med, Dept Epidemiol & Biostat, NL-3000 DR Rotterdam, Netherlands
[2] TNO, Gaubius Lab, NL-2300 AK Leiden, Netherlands
[3] Leiden Univ, MGC Dept Human Genet, Leiden, Netherlands
[4] Univ Antwerp VIB, Dept Biochem, Born Bunge Fdn, Neurogenet Lab, Antwerp, Belgium
[5] Univ Leiden Hosp, Dept Cardiol, NL-2300 RC Leiden, Netherlands
[6] Univ Leiden Hosp, Dept Internal Med, NL-2300 RC Leiden, Netherlands
来源：
NEUROSCIENCE LETTERS | 1998年 / 248卷 / 01期
关键词：
apolipoprotein E; serum level; plasma; dementia; Alzheimer's disease; atherosclerosis;
D O I：
10.1016/S0304-3940(98)00339-5
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
The APOE*4 allele of the apolipoprotein E gene (APOE) is an important risk factor for Alzheimer's disease. It has been suggested that levels of apolipoprotein E (apoE) in plasma are increased in Alzheimer's disease. In this population-based study, we found that serum apoE levels were lower in Alzheimer patients compared to non-demented controls (0.75 mu mol/l (SD 0.35), vs. 0.83 mu mol/l (SD 0.40), P < 0.05). This finding is in accordance with lower serum apoE levels as observed in carriers of the APOE*4 allele, who are over-represented in Alzheimer's disease. After adjustment for age, sex, total protein, albumin level, body mass index and the APOE genotype, the difference in serum apoE levels largely disappeared. Our population-based study suggests that the differences in serum apoE level between Alzheimer patients and controls are mainly the result of differences in the distribution of the APOE genotype. (C) 1998 Elsevier Science Ireland Ltd.
引用
收藏
页码：21 / 24
页数：4
相关论文
共 18 条
[1]  
[Anonymous], 1987, DIAGNOSTIC STAT MANU, V4th
[2]   ASSOCIATION OF APOLIPOPROTEIN-E GENOTYPE WITH BRAIN LEVELS OF APOLIPOPROTEIN-E AND APOLIPOPROTEIN J(CLUSTERIN) IN ALZHEIMER-DISEASE [J].
BERTRAND, P ;
POIRIER, J ;
ODA, T ;
FINCH, CE ;
PASINETTI, GM .
MOLECULAR BRAIN RESEARCH, 1995, 33 (01) :174-178
[3]   DECREASED HDL2 AND HDL3 CHOLESTEROL, APO A-I AND APO A-II, AND INCREASED RISK OF MYOCARDIAL-INFARCTION [J].
BURING, JE ;
OCONNOR, GT ;
GOLDHABER, SZ ;
ROSNER, B ;
HERBERT, PN ;
BLUM, CB ;
BRESLOW, JL ;
HENNEKENS, CH .
CIRCULATION, 1992, 85 (01) :22-29
[4]   PREVALENCE OF APOLIPOPROTEIN-E PHENOTYPES IN ISCHEMIC CEREBROVASCULAR-DISEASE - A CASE-CONTROL STUDY [J].
COUDERC, R ;
MAHIEUX, F ;
BAILLEUL, S ;
FENELON, G ;
MARY, R ;
FERMANIAN, J .
STROKE, 1993, 24 (05) :661-664
[5]   IMMUNODETECTION OF THE AMYLOID-P COMPONENT IN ALZHEIMERS-DISEASE [J].
DUONG, T ;
POMMIER, EC ;
SCHEIBEL, AB .
ACTA NEUROPATHOLOGICA, 1989, 78 (04) :429-437
[6]   CLINICAL-NEUROPATHOLOGICAL CORRELATIONS IN ALZHEIMERS-DISEASE AND RELATED DEMENTIAS [J].
GALASKO, D ;
HANSEN, LA ;
KATZMAN, R ;
WIEDERHOLT, W ;
MASLIAH, E ;
TERRY, R ;
HILL, R ;
LESSIN, P ;
THAL, LJ .
ARCHIVES OF NEUROLOGY, 1994, 51 (09) :888-895
[7]   Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study [J].
Hofman, A ;
Ott, A ;
Breteler, MMB ;
Bots, ML ;
Slooter, AJC ;
vanHarskamp, F ;
vanDuijn, CN ;
Van Broeckhoven, C ;
Grobbee, DE .
LANCET, 1997, 349 (9046) :151-154
[8]   DETERMINANTS OF DISEASE AND DISABILITY IN THE ELDERLY - THE ROTTERDAM ELDERLY STUDY [J].
HOFMAN, A ;
GROBBEE, DE ;
DEJONG, PTVM ;
VANDENOUWELAND, FA .
EUROPEAN JOURNAL OF EPIDEMIOLOGY, 1991, 7 (04) :403-422
[9]   Distortion of allelic expression of apolipoprotein E in Alzheimer's disease [J].
Lambert, JC ;
PerezTur, J ;
Dupire, MJ ;
Galasko, D ;
Mann, D ;
Amouyel, P ;
Hardy, J ;
Delacourte, A ;
ChartierHarlin, MC .
HUMAN MOLECULAR GENETICS, 1997, 6 (12) :2151-2154
[10]   PHENOTYPES OF APOLIPOPROTEIN-B AND APOLIPOPROTEIN-E AFTER LIVER-TRANSPLANTATION [J].
LINTON, MF ;
GISH, R ;
HUBL, ST ;
BUTLER, E ;
ESQUIVEL, C ;
BRY, WI ;
BOYLES, JK ;
WARDELL, MR ;
YOUNG, SG .
JOURNAL OF CLINICAL INVESTIGATION, 1991, 88 (01) :270-281
12